Article Details

IFM Therapeutics launches cGAS/STING-focused subsidiary for inflammatory and autoimmune ...

Retrieved on: 2019-02-10 21:34:26

Tags for this article:

Click the tags to see associated articles and topics

IFM Therapeutics launches cGAS/STING-focused subsidiary for inflammatory and autoimmune .... View article details on hiswai:

Excerpt

<div>The NLRP3-focused IFM Tre debuted last July with a $31 million series A, drawn from the likes of <b>Atlas Venture</b>, Abingworth and Bristol-Myers Squibb, ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up